Author:
Schöffski P.,Taron M.,Jimeno J.,Grosso F.,Sanfilipio R.,Casali P.G.,Cesne A. Le,Jones R.L.,Blay J.-Y.,Poveda A.,Maki R.G.,Nieto A.,Tercero J.C.,Rosell R.
Reference27 articles.
1. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata;Rinerhart;J Org Chem,1990
2. European Medicines Agency. Pre-Authorisation Evaluation of Medicines for Human Use. Committee for Medical Products for human use. Summary of positive Opinion for Yondelis. Doc. Ref. EMEA/CHMP/316962/2007. London, 19 July 2007.
3. Trabectedin and its potential in the treatment of soft tissue sarcoma;Cassier;Ther Clin Risk Manag,2008
4. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma;Schöffski;Expert Opin Pharmacother,2008
5. Therapeutic impact of ET-743 (Yondelis®, Trabectidin) a new marine derived compound in Sarcoma;Jimeno;Curr Opin Orthop,2003
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献